Add time:07/12/2019         Source:sciencedirect.com

No new and effective treatments have been approved for the treatment of esophageal squamous cell carcinoma (ESCC) in the past decade. Cisplatin and 5-fluoruracil are the most commonly used drugs for this disease. In order to develop a new class of drugs effective in our ESCC phenotypic screens, we began a systematic approach to generate novel compounds based on the 2-oxo-1,2-dihydroquinoline-4-carboxamide fragment. Herein, we report on the synthesis and initial assessment of 55 new analogues in two ESCC cell lines. Some of the active analogues with IC50 values around 10 μM were tested in three additional cell lines. Our structure-activity relationships revealed remarkable alterations in the anti proliferative activities upon modest chemical modifications and autophagy modulation is a suggested mechanism of action.

We also recommend Trading Suppliers and Manufacturers of 2-hydroxy-4-oxo-N-[3-(trifluoromethyl)phenyl]-1,4-dihydroquinoline-3-carboxamide (cas 5554-20-1). Pls Click Website Link as below: cas 5554-20-1 suppliers